Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistNWL Netherlands Services B.V., a drug manufacturing facility in the Netherlands, was cited for significant Current Good Manufacturing Practice (CGMP) violations that rendered their finished pharmaceutical products adulterated. The company failed to conduct adequate investigations into out-of-limit microbial contamination results in a critical manufacturing system, including seven contamination events in 2024 with results as high as 10,000 CFU/mL, and did not perform sufficient root cause analysis, corrective actions, or preventive actions (CAPAs) for batch discrepancies. The facility's inadequate investigation protocols were particularly concerning because the contaminated component from this system was used as a major component in their drug products.